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1. INTRODUCTION 32 
 The discovery of pharmacologically active compounds has been a long standing goal of 33 
medicine since its inception. Our hunter-gatherer ancestors sought to use the diverse products 34 
found in nature to provide relief and cure from their ailments and this approach remained 35 
unchanged for millennia. Indeed, early pharmacologists focused on natural substances, 36 
mainly extracts derived from plants. Interestingly, many pharmacologically active natural 37 
products (NPs) used in modern medicine began as complex mixtures of compounds similar to 38 
our ancestor’s approaches. However, modern approaches aimed at identifying and purifying 39 
the active NP(s) present within these mixtures. This process has often resulted in the 40 
development of novel pharmacological ingredients from a wide variety of biological 41 
materials. An analysis of the rate of novel chemical entity (NCE) approvals from the period 42 
of 1981 to 2014 demonstrates that the field of NPs is still highly represented with a mean of 43 
34±9% in the last 15 years [1]. From the number of NPs developed a significant proportion 44 
were derived from plant extracts [2]. Indeed, it has been repeatedly shown that plants contain 45 
a diverse set of compounds and that some of these have shown pharmacological activity 46 
towards a variety of diseases [2]. Finding a set of bioactive compounds among the sheer 47 
diversity of the compounds present in plant tissues, estimated at 200,000 different metabolites 48 
[3], comprises a significant challenge. Furthermore, purification may be hindered by the 49 
limitation of biological material available and/or synergistic/antagonistic effects that might be 50 
lost as extracts attain higher degrees of purity. Developments in the field of metabolomics in 51 
the past 20 years have facilitated improvements in the accuracy, sensitivity, throughput and 52 
data analysis capacity and have contributed significantly towards the field of discovery of 53 
new bioactive biomolecules from plants. This review addresses the developments in 54 
metabolomics in the context of bioactive discovery. 55 
2. SOURCES OF NEW DRUGS AND BIOACTIVE COMPOUNDS 56 
Novel bioactive compounds can be classified according to their origin. For example, novel 57 
compounds are often characterised as NPs, botanical drugs (defined mixture), NP derivatives, 58 
synthetic drugs and mimics of NPs [1]. The early 2000s saw the development of high-59 
throughput screening (HTS) based on biochemical targets which allowed many pure 60 
compounds to be screened in a relatively short time. The combination of HTS with modern 61 
combinatorial chemistry opened up the possibility of generating libraries comprising millions 62 
of compounds and screening these for efficacy in a relatively short period of time. However, 63 
the enormous scale of this approach did not translate into a significant increase in the number 64 
novel drugs developed. In fact, the number of de novo FDA approved compounds developed 65 
has been fairly modest, with Sorafenib, an anticancer drug, the most successful output [1]. 66 
The limited success has been attributed to the randomness of the approaches which may 67 
result in a lack of NCEs with high diversity [4].  68 
This resulted in a shift toward smaller-scale compound collections based on NP scaffolds and 69 
more focused in chemical diversity [2]. With the growing realisation that the chemical 70 
diversity present in NPs has had enormous success with respect to the development of novel 71 
drugs, in comparison with high-throughput synthetic chemistry approaches, there has been 72 
resurgence in the application of natural chemical diversity to the field of drug discovery [5-73 
7]. Indeed, NP molecules tend to have a higher number of chiral centers, oxygen atoms and a 74 
lower number of sulfur, nitrogen and halogen-containing groups [6] as well as a lower ratio 75 
of aromatic ring atoms to total heavy atoms in comparison with synthetic compounds [8]. 76 
Since its inception in the middle of the 19th century, the history of modern synthetic 77 
chemistry represents a small fraction of time compared with the millennia associated with 78 
natural chemical evolution and diversity. The production of some of these substances has 79 
often been a determinant factor whether organisms would survive in hostile environments 80 
often providing a significant advantage over competing organisms. This explains the 81 
relatively higher percentage of biologically active substances from natural sources when 82 
compared with substances obtained from purely synthetic sources [4]. Approximately 25% of 83 
about 1 million NPs are biologically active (i.e. show toxicity or a positive activity) with 84 
approximately 60% of these products derived from plants and the remaining by microbes and 85 
animals to lesser extent [9]. NPs to this day remain important sources of biologically active 86 
compounds and during the period of 1981-2014 approximately 60% of NCEs approved are 87 
represented by NPs, NP derivatives and mimics of NPs [1]. Indeed, NPs may be isolated from 88 
diverse biological sources such as, animal, fungi, bacteria, marine organisms and plants and 89 
there has been an increasing realisation of the contribution of global biodiversity towards 90 
affordable therapeutical solutions for the majority of the population in the world [7]. 91 
3. BIODIVERSITY AND NATURAL PRODUCT DISCOVERY 92 
Global biodiversity has great potential for providing novel sources of NPs, and indeed it has 93 
provided a significant contribution to the repertoire of pharmaceutical products currently 94 
available. Despite many successful examples of NPs used for the development of novel 95 
pharmaceuticals, the enormous biodiversity present remains largely untapped. Many 96 
successful pharmaceutical products such as penicillin and statins derive from Fungi but these 97 
comprise a total of approximately 100,000 known species although the total number is 98 
estimated to be ten-fold higher [10]. Prokarya and Animalia have also provided important 99 
novel antimicrobial agents such as chloramphenicol and streptomycin from prokaryotes [9] 100 
and Hadruirin from animal sources [11]. Animalia species numbers are estimated at 101 
7,770,000 and 2 150,000 species present in terrestrial and marine environments, respectively, 102 
[12] whereas estimates for number of Prokaryote species remain unknowable in any scale in 103 
the environment [13]. Marine eukaryotic organisms are also being increasingly seen as a 104 
potential source of NPs with sponges, macroalgae and seaweeds reported to provide a wealth 105 
of NPs with anticancer and antiviral properties [14, 15]. The total number of marine species 106 
is estimated at 0.7-1.0 million species including 226,000 Eukariotic species which inhabit an 107 
extreme diversity of environments with respect to pressure, salinity and temperature [16]. 108 
Interestingly, the total number of described plant species pales in comparison with the 109 
aforementioned groups with the estimate of the total number of plant species at about 110 
320,000, although some studies estimate this number to be as high as 450,000 [17]. Despite 111 
this, the distribution of drugs based on NPs across different stages of drug development and 112 
according to their biological origin (Plant, Bacterial, Fungal, Animal or semi-synthetic) 113 
highlights that plants are important sources of NPs for biomedical applications [2]. Indeed, 114 
out of the 225 drugs derived from NPs undergoing development in 2008, 108 were from plant 115 
origin alone which significantly outnumbers any of the other origin classes (25, 7, 24 and 61 116 
for bacterial, fungal, animal and semisynthetic origin, respectively) [2]. Indeed there are 117 
many well-known examples of plant-derived drugs which include anticancer-drugs most 118 
notably paclitaxel (taxol), a diterpenoid compound isolated from the bark of Taxus brevifolia 119 
etoposide (vepesid) partly synthesized from the a lignin isolated from Podophyllum peltatum 120 
(podophyllotoxin) and irinotecan which is a derivative from an alkaloid extracted from 121 
Camptotheca acuminata [1, 18]. 122 
4. FROM TRADITIONAL MEDICINE TO THE DEVELOPMENT OF NOVEL 123 
DRUGS 124 
Plants have been seen not only as a source of energy and nutrition but have been exploited in 125 
traditional medicine throughout humanity’s history. The oldest records of usage of medicinal 126 
plants dates back to 2400 B.C. from Mesopotamia but more recent records are also available 127 
from Ancient Egypt and China [7]. Indeed, NPs particularly from plants have been at the 128 
forefront of medicine since ancient times until the isolation of morphine by Sertürner around 129 
1804 [7]. During that period, a large wealth of ethnobotanical knowledge was acquired over 130 
countless generations and constituted the foundation of traditional and indigenous peoples 131 
medicinal knowledge. Only with the advent of the scientific revolution in the 18th century 132 
has medicine shifted from the application of herbal crude preparations to the isolation and 133 
development of the active ingredients within the plant tissues. Despite unprecedented 134 
developments in modern medicine it is still worth noting that a large proportion of the world 135 
population still relies on traditional remedies (often plant-based) as the main source of 136 
healthcare [19, 20]. With the continuous growth in the use of medicinal herbal products, 137 
issues concerning their safe use are being increasingly highlighted [20] with the lack of 138 
pharmacological and clinical data of such products seen as a major impediment to their 139 
integration into conventional medical practices [21]. Therefore, a number of studies have 140 
been focused on providing such data such as that of the clinical studies of Rhodiola rosea as a 141 
therapeutical agent for depression related conditions [22]. These examples highlight not only 142 
the therapeutic potential of botanical products but also the need to investigate further the 143 
mechanisms of action, the bioactive ingredients and the safe use of such products. The 144 
discovery of novel ingredients in traditional medicine often involved direct experimentation 145 
of prospective medicines in humans utilising crude preparations of biological tissues with 146 
minimal considerations regarding scientific methodology. This approach raises unacceptable 147 
safety and ethical issues, and promises very little with respect to significant success rates by 148 
modern standards. However, there were no other alternatives available until the last 200 149 
years. 150 
5. BIOPROSPECTION OF NATURAL PRODUCTS 151 
Several technological, medical and scientific advances eventually led to a shift towards 152 
isolation of pure compounds. Many such botanical products have been targeted with the goal 153 
of discovering commercially valuable bioactive NPs in a process known as natural product 154 
bioprospection [23].With an estimate of plant/crop diversity of 200,000 compounds [3], many 155 
of which possess bioactive properties, the teasing out of specific bioactivity becomes 156 
incredibly difficult. Traditionally, the discovery of bioactive NPs from biological material 157 
involved the collection and screening of plant material utilising biological assays. From this 158 
step onwards there are two leading approaches utilised in the discovery of bioactivity relying 159 
on bioassay-guided fractionation and pure compound screening [24, 25] (Figure 1). The 160 
bioassay-guided fractionation approach seeks to reduce the complexity of the extracts down 161 
to its single bioactive components by utilising repeated series of fractionation and bioassay 162 
testing until the successful isolation of an active NP [24]. Several fractionation 163 
methodologies are available for separating crude extracts into fractions of reduced 164 
complexity. Solvent partitioning is a popular approach in which samples are extracted 165 
sequentially using solvents of differing polarity and, while it requires minimal capital 166 
investment, it provides limited separation capacity, is labour intensive and requires the 167 
extensive use of organic solvents [25] which may be problematic for bioassays. Liquid-168 
chromatography (LC) separation methods which include LC, High performance LC (HPLC), 169 
Ultra performance LC (UPLC) and counter-current chromatography are popular methods of 170 
offline and online separation of complex mixtures [26]. Although challenging, it is possible 171 
to couple LC techniques to post-column biochemical assays and parallel chemical analysis 172 
which may aid the identification of bioactive compounds from crude extracts [27]. Gel-173 
chromatography has also been modestly used in applications where targeted molecules 174 
include proteins and other biopolymers and while separation efficiency is modest, the 175 
aqueous composition is often compatible with bioassays [26]. Thin layer chromatography 176 
(TLC) is also a popular separation technique particularly when coupled to bioassays and 177 
allows the separation and bioassay to occur under the same experimental conditions within 178 
the same plate thereby allowing several samples to be analysed simultaneously utilising less 179 
solvent. On the other hand when compared with liquid chromatographic methods it does have 180 
lower separation efficiency [28]. Affinity chromatographic methods provide an additional 181 
targeted method which relies on the binding of biomolecules with artificially generated 182 
antibodies or synthetic ligands allowing the enrichment of biomolecules with targeted traits in 183 
the fractions [26]. Bioassays are often categorised as isolated molecular target assays, cell-184 
free multicomponent assays or cell-based assays. The former is usually based on assessing 185 
specific interactions between purified enzymes (eg. proteases, kinases) and pure compounds 186 
whereas the second includes assays on activities derived from cell extracts, cell membranes 187 
or reconstituted signalling pathways [29]. The later utilises cell-models and is generally based 188 
on the assays which monitor reporter genes or phenotypic responses resulting from intact 189 
cellular processes [29]. Regardless of the bioassay strategy being utilised, the bioassay-190 
guided “offline” fractionation process is an iterative process that ultimately depends on the 191 
availability of preparative-scale analytical methods that allow for the resolution of complex 192 
mixtures of primary and secondary metabolites that are typical from the source organisms 193 
and result in a purified natural compound ideally as a single chemical entity with a specific 194 
activity [30]. This approach allows fractions with no bioactivity to be excluded and will 195 
generate bioactive fractions of reduced chemical complexity, however it requires an abundant 196 
source of biological material and may often lead to the isolation and identification of known 197 
bioactive compounds in a process known as replication [25]. A literature survey indicates that 198 
the average number of isolation steps involved in the purification of NPs is less than three 199 
[30] and the authors suggested that compounds that are often present in low concentrations 200 
are rarely pursued due to their arduous isolation process. Indeed, the effort required to purify 201 
a single chemical entity depends on the concentration of the NP, the physico-chemical 202 
properties (eg. solubility and crystalisation), the use of appropriate selectivity characteristic 203 
of the separation technique chosen for the target NP, and the nature of the matrix of the crude 204 
extract [30]. 205 
An alternative approach aims to isolate and elucidate the structure of the majority of the 206 
secondary metabolites present in the crude extract and subsequently test pure compounds (ie 207 
standards) for bioactivity (Figure 1). The nature of this approach allows the selection of 208 
extracts which contain compounds which are not already present in the libraries of pure 209 
compounds with recorded bioactivities [24]. Both the cited approaches should aim to identify 210 
as many NPs present in the extracts at the earliest opportunity in order to avoid redundant 211 
work in a process known dereplication [24, 25]. The most common methodologies used for 212 
this purpose often combine a separation step, usually a chromatography-based separation 213 
which attempts to resolve crude extracts into separate metabolites, linked to a structure 214 
elucidation step which would typically involve mass-spectrometry (MS) or nuclear magnetic 215 
resonance (NMR) technologies [24]. This type of approach is well aligned with the prevalent 216 
paradigm of drug development of the past few decades in which single proteins whose 217 
inhibition is likely to be involved in the treatment of a targeted disease are identified and 218 
subsequently are tested against large libraries of small-molecules in order to identify lead 219 
molecules which will be further tested in appropriate and complex model (ex vivo an in vivo) 220 
[31]. The discovery of novel drugs according to this approach often aims to identify 221 
compounds that would act/bind specific targets. However, advances in genomics and 222 
proteomics highlight natural variation present in individuals, which might be associated with 223 
lack of global drug effectiveness due to individual mutations/polymorphisms that are not 224 
present in the model target protein screened. In addition, individual variation in gut 225 
microbiome content and composition can modulate the response to drug therapies [32]. 226 
Furthermore, when addressing antimicrobial/antiviral drugs a single target approach is 227 
generally more vulnerable to the development of resistance to novel medicines. Indeed, a 228 
combination of antiretroviral drugs that target different viral proteins is often found to be 229 
more effective [33]. As a result, novel paradigms are arising, which include system-level 230 
thinking approaches such as computational multitarget screening [31] and the development of 231 
high-throughput combination screening platforms [34]. The rekindled interest in system-level 232 
thinking has been aided by the development of high-throughput ‘omics’ platforms that are 233 
able to generate large amounts of reproducible molecular data and large curated databases 234 
integrating data from different disciplines and the large development of interdisciplinary 235 
research with the goal of integrating and mining these datasets [35]. As the paradigm in drug 236 
discovery shifts toward system-level approaches with respect to the screening of multiple 237 
targets and multiple effectors, so must the process of bioactive NP discovery from plant 238 
material. Indeed, in many cases, it is the combination of metabolites rather than a unique 239 
chemical entity that is responsible for the bioactive properties of crude preparations of 240 
biological material. For example, it has been observed that testing a mixture of the two major 241 
bioactive alkylphthalides (Z-ligustilide and n-butyldenephtalide) identified through bioassay-242 
guided fractionation of Angelica sinensis roots yields lower anti-endothelial activities when 243 
compared to the crude volatile oil obtained which indicates potential synergistic effects with 244 
unknown compounds [36]. Furthermore, Skirycz et al (2016) cites the example of the use of 245 
flowers and fruits of Psychotria colorata in native American traditional medicine to treat 246 
pain. The analgesic effect was confirmed in rodents [37], and several alkaloids in 247 
combination were identified as the active ingredients [23]. Interestingly, the major 248 
compounds identified include hodgkinsine and psychotridine, which are opioid agonist and a 249 
N-methyl-D-aspartate receptor antagonist, respectively [38, 39]. The complex mixture of 250 
agonist-antagonist compounds in crude extracts may allow additive, synergistic and 251 
antagonistic interactions between metabolites that underpin the medicinal properties of plant 252 
extracts [23]. The complexity of these metabolite interactions and their contribution towards 253 
the bioactivity of plant extracts is in contrast to the standard aforementioned approach used in 254 
NP discovery (e.g. bioassay guided isolation of pure compounds). Indeed, it is not uncommon 255 
for the fractionation of bioactive crude extracts to generate non-bioactive extracts [36, 40]. 256 
Consequently, many advocate that a shift away from less reductionist approaches towards 257 
systems biology approaches is warranted [23, 41-43]. The fields of genomics, proteomics and 258 
metabolomics have experienced great advances in the last 20 years which have allowed 259 
system biology approaches to become a reality. While the application of genomics and 260 
proteomics to the field of drug discovery has been a relatively recent event, the use of some 261 
analytical tools utilised in metabolomics such as hyphenated MS and NMR have been central 262 
in the discovery of NPs since the 1970s. However, technical developments in instrumentation 263 
and post-separation and acquisition data analysis in the past two decades have increased the 264 
throughput of such analytical tools and resulted in naming the field ‘metabolomics’.   265 
6. METABOLOMICS: BRAVE NEW (DATA) WORLD 266 
The term metabolomics was coined in 1998 by Oliver et al and refers to the study of the 267 
quantitative and qualitative collection of all the metabolites in a given cell or tissue [44]. 268 
Since then, there has been a growing interest in applying metabolomics methods particularly 269 
in the field of plant sciences [45-48]. Applications of metabolomics usually include NMR- 270 
and MS-based approaches often coupled to chromatographic separations and are diverse in 271 
scope. These include studies with the goals of understanding how metabolic networks 272 
respond in plants exposed to environmental stresses [49-51], monitoring unintended 273 
metabolic effects in genetically-modified crops [52-54], discovery of novel NPs [55, 56] 274 
amongst many others. Metabolomics approaches have been reviewed extensively elsewhere 275 
[23, 45, 46, 57] and the nature of these approaches has often been categorised either as a 276 
targeted, metabolite profiling or metabolite fingerprinting. The first aims to extract and 277 
quantify a limited predetermined set of metabolites by optimising linear ranges, efficiency 278 
and robustness of extraction, and stability of the target compounds in detriment of non-target 279 
compounds. Examples of this type of approach include the quantification of polyphenols in 280 
berries [58], identification and quantification of loline-type alkaloids in endophyte-infected 281 
grasses of the genera Lolium and Festuca [59] and quantification of glucosinolates from 282 
Camelina sativa seeds [60]. However, the main limitation of the targeted approach is that it 283 
provides no information regarding non-targeted metabolites which may be pathway related or 284 
relevant for the objective of the study [61].  285 
Metabolite profiling, which can be defined as analysis of a group of selected pre-defined 286 
metabolites (e.g. polyphenols, carbohydrates or fatty acids), is also affected by the limitations 287 
cited above, however it differs from targeted analysis due to including a broader range of 288 
metabolites and may include known and unknown metabolites and often providing semi-289 
quantitative rather than absolute quantitative information [23,62,63]. There is an extensive 290 
body of literature documenting the application of this type of approach but some examples 291 
include the monitoring of primary metabolites under environmental stress conditions 292 
[50,64,65] monitoring primary and secondary metabolites in genetically modified crops [54]. 293 
Conversely, truly untargeted approaches attempt to be as comprehensive as possible while 294 
minimising bias towards any classes of compounds. It is generally regarded that there is no 295 
“one method to rule them all” that allows a comprehensive coverage of the entire 296 
metabolome, and that the choice of sample preparation, extraction and analytical tool 297 
inevitably introduces bias towards certain classes of metabolites [66]. This limitation is often 298 
overcome by combining multiple strategies for analysis that complement each other’s 299 
weaknesses.  300 
Metabolite fingerprinting is an untargeted approach that focuses in the recognition of patterns 301 
in spectra (usually NMR and MS) collected from the analysis of sample extracts without 302 
attempting to quantify or identify specific compounds [62]. This is often achieved by 303 
applying multivariate pattern recognition tools such as principal component analysis (PCA) 304 
and discriminant function analysis (DFA) in order to identify metabolic features that 305 
differentiate groups of samples [62]. Multivariate analysis has been associated with studies of 306 
biomarker discovery and disease diagnostic [67] and it has also been used to distinguish 307 
different plant species and ecotypes [68, 69]. Despite the global, unbiased nature of this 308 
approach (as discussed above) the initial workflows did not include automated metabolite 309 
annotation, and therefore, annotation of metabolites was usually performed manually in a 310 
time-intensive process, which was usually reserved to the compounds of interest such as 311 
potential biomarkers. This approach is still currently relevant; however, advances in 312 
metabolomics workflows are blurring the once distinct division between profiling and 313 
fingerprinting methods. Indeed the past 15 years have seen great advancements in pre-314 
processing and processing of data particularly from MS-based technologies coupled to 315 
chromatographic separation. This can be illustrated by the wealth of pre-processing and 316 
processing tools available both from commercial and instrument vendors but also as open-317 
source tools. Some examples of these tools include XCMS [70], XCMS online [71], 318 
TAGfinder [72], Sieve (Thermo Fisher Scientific Inc) [73], MassHunter Profinder (Agilent 319 
Technologies) MarkerLynx (Waters), Progenesis QI (Nonlinear Dynamics) [74], Marker 320 
View (AB Sciex), MZmine 2 [75], Metalign [76] amongst many others. 321 
These tools are often incorporated in workflows which allow detected features to be 322 
processed, molecular formulas to be generated, and subsequently, queried against metabolite 323 
databases from various sources (e.g. online, commercial, in-house databases). Indeed the 324 
integration of automated annotation in untargeted analysis can be seen as a hybrid of 325 
metabolite fingerprinting and metabolite profiling particularly when tailored databases are 326 
utilised. For example, Skogerson et al (2011) developed an automated peak annotation and 327 
database system for the analysis of complex volatile mixtures by gas-chromatography 328 
coupled to mass spectrometry (GC-MS) allowing the annotation of large datasets comprising 329 
of hundreds to thousands of samples [77]. The process of automated annotation is highly 330 
dependent on the quality of source database utilized, and although targeted biological 331 
databases often provide promising results, it is not unusual for compounds to be wrongly 332 
annotated. Therefore, the metabolomics community encourages studies to categorise the 333 
certainty level of compound identification according to a set of guidelines based on the 334 
degree of evidence provided [78, 79].  335 
6.1. NMR-based metabolomics 336 
 NMR spectroscopy allows molecules containing one or more atoms with a non-zero 337 
magnetic field to be  detected that include 1H, 13C, 14N, 15N and 31P [80, 81]. This technique 338 
allows the characterisation of metabolites with at least one NMR signal with respect to their 339 
frequency (chemical shift), intensity and magnetic relaxation properties depending on the 340 
chemical environment that the nucleus occupies [80]. NMR spectra, via varied pulse 341 
techniques, often provide structural information which is essential for the identification of 342 
unknown compounds and it is used routinely in NP discovery. Additionally, it is possible to 343 
obtain quantitative data from NMR spectra which may be of interest to several types of 344 
metabolomics approaches. Indeed, NMR has been used in many metabolomics approaches 345 
which include the metabolite profiling of opium poppy [56] and metabolic flux analysis of 346 
linseed embryos [82]. NMR has been extensively used in fingerprinting approaches as spectra 347 
are often too convoluted [61]; however, many groups have addressed convolution by 348 
coupling liquid-chromatography separation prior NMR analysis [83]. Despite its applications, 349 
LC-NMR approaches have inherent limitations such as significant capital costs, solvent 350 
suppression [83, 84] and perhaps, more importantly, the relatively low sensitivity of NMR 351 
which often limits the analysis to the most abundant compounds [61, 80, 81, 83] (Figure 2).  352 
6.2. Mass spectrometry-based metabolomics 353 
Mass spectrometry has become the de rigueur approach used in metabolomics due to its high 354 
sensitivity and wide metabolite coverage. Overall, this technique relies on the ionisation of 355 
chemical compounds, most commonly utilising Electron Ionisation (EI), Electrospray 356 
Ionisation (ESI) and Atmospheric pressure chemical ionization (APCI), generating charged 357 
molecules or molecule fragments which are subsequently measured with respect to their 358 
mass-to-charge ratio (m/z) and abundance. Often crude extracts are analysed through direct 359 
infusion-mass spectrometry (DI-MS) generating a single mass spectrum representing the 360 
global metabolite profile of the sample. Utilising this approach it is possible to achieve a very 361 
high-throughput metabolite fingerprinting approach (first pass) which can be applied in a 362 
variety of plant tissues [85, 86]. As there is no separation prior to analysis, this type of 363 
approach is usually carried out on high mass accuracy instruments as it allows the distinction 364 
between some compounds with the same nominal mass [66]. However, this technique does 365 
not allow isomers to be differentiated due to their identical molecular masses [87]. 366 
Furthermore, as multiple compounds are analysed simultaneously in the mass spectrometer 367 
this technique is particularly vulnerable to ion co-suppression effects in which non-volatile 368 
compounds influence the ionization and transfer of metabolites from liquid to gas phase in an 369 
ESI source leading to a misrepresentation of the signals present in the mass spectrum [66]. In 370 
order to prevent and minimize these effects, metabolomics approaches often resort to 371 
coupling mass spectrometers with separation techniques such as GC, LC or electrophoretic 372 
separation such as capillary electrophoresis [61] (Figure 2). 373 
GC-MS has seen extensive use in plant metabolite profiling of primary metabolites ranging 374 
from studying plant metabolic responses to abiotic stress [50], analysis of the volatile profiles 375 
of Allium samples [88], to the mapping quantitative trait loci for metabolites in tomato fruits 376 
[89]. This approach requires that the target compounds are volatile in the operating range of 377 
the GC usually 100-320 °C which in many cases may require compounds to be extracted 378 
from biological material and subsequently derivatised to ensure their volatility. This 379 
requirement for volatility comes at a cost as only the compounds amenable to derivatisation 380 
may be analysed [90]. Despite this limitation, GC-MS applied in the context of metabolomics 381 
allows the simultaneous detection of several hundred different chemical compounds ranging 382 
from organic acids, sugars to amino acids fatty acids and aromatic amines [61]. Indeed, GC 383 
provides a high separation efficiency allowing compounds with mass spectral similarities 384 
such as isomers and enantiomers to be distinguished and produces reproducible retention 385 
times that allow comparison of results derived from different labs. Upon chromatographic 386 
separation, metabolites are usually ionised by electron ionisation (EI), which is regarded as a 387 
reproducible approach generally unaffected by ion co-supression [87]. The reproducible 388 
nature of this approach allows mass spectrum and kovat retention indexes to be used in 389 
querying readily available MS databases containing hundreds of thousands of compounds 390 
such as the NIST standard reference database 14 (https://www.nist.gov/srd/nist-standard-391 
reference-database-1a-v14), Golm Metabolome database [91] and FiehnLib [92]. 392 
Liquid-chromatography coupled to mass spectrometry (LC-MS) takes advantage of the 393 
separating power of liquid chromatography techniques that allow the study of high molecular 394 
weight compounds that cannot be analysed by GC-MS [87]. When coupled to high resolution 395 
MS instruments this constitutes a powerful technique for analysis of a broad range of 396 
secondary metabolites. It is used broadly not only in metabolomics studies but also in natural 397 
product chemistry studies. Indeed, LC does not require analytes to be volatile or derivatised 398 
prior to LC analysis, and allows for a wide range of analyte polarity and mass range [90], 399 
consequently, sample preparation is generally less complex. Following chromatographic 400 
separation the metabolites are ionised (generally by ESI or APCI) and mass spectrometers 401 
generally allow for positive and negative modes of operation. Metabolites often ionise more 402 
efficiently in one mode over another so the monitoring of data in both positive and negative 403 
ionisation modes allows a more comprehensive coverage of the metabolome [66]. Generally, 404 
ionisation techniques utilised in LC-MS are softer ionisation techniques when compared to 405 
EI, which is commonly utilised in GC-MS approaches, and provide spectra much less 406 
dominated by fragments. The limited number of fragments observed in LC-ESI-MS often 407 
limits the discrimination of isomeric compounds so mass spectrometrists often design 408 
tandem-MS (MSn) methods which aim to fragment selected ions utilising collision-induced 409 
dissociation [93]. The fragmentation patterns observed can then be compared against 410 
fragmentation databases of known compounds. However, instrument variability and matrix 411 
effects (e.g. presence of co-eluting compounds or ionic salts) can impact the ionisation 412 
efficiency of the instrument and may also interfere with the chromatography which ultimately 413 
leads to a lack of reproducibility which contributes to the great challenge of comparing data 414 
generated from difference sources.  415 
6.3. Combining multiple analytical tools 416 
Despite the high sensitivity of MS-based methods, they are ultimately limited with respect to 417 
metabolite structure elucidation and it is largely impossible to determine unambiguously the 418 
structure of a metabolite utilising MS-based methodologies alone regardless of the accuracy 419 
of the instrument [94]. Indeed, MS-based metabolomics methods provided relatively low 420 
discovery rates and often result in false identifications with a relatively low number of 421 
metabolites which can be assigned an identity with a high degree of confidence [95]. 422 
Ultimately it is the availability of authentic standards or the requirement to purify individual 423 
metabolites followed by NMR analysis for structure elucidation that remain the only 424 
strategies that allow high-confidence level in the identification of metabolites. Therefore it is 425 
not unusual for bioprospecting studies to incorporate results from these two analytical 426 
approaches in order to provide unambiguous identification of metabolites. 427 
 428 
Interestingly, in face of the limitations associated with both MS and NMR-spectroscopy 429 
approaches there have been efforts to combine these techniques in an hyphenated approach. 430 
By interfacing LC with NMR and MS analysis (e.g. LC-NMR-MS)  it is possible to capitalise 431 
on the strengths and mitigate the weaknesses of each of techniques providing comprehensive 432 
structural data that can aid in addressing the bottleneck of compound identification in extracts 433 
[96, 97]. This approach was applied to E. coli extracts and permitted the correct identification 434 
of a wide range of metabolites including amino acids, nucleic acids and carbohydrates [98]. 435 
Currently, there is no single procedure that allows the quantification and identification of the 436 
entire metabolite complement in any tissue. The choice of sampling and extraction procedure 437 
as well as the analytical tool applied will inadvertently introduce bias in the analysis, thus the 438 
methodologies should be adjusted in order to obtain the most relevant and comprehensive 439 
metabolite coverage possible for the study. 440 
7. METABOLOMICS FOR SCREENING BIOCHEMICAL DIVERSITY AND 441 
CHEMOTAXONOMY 442 
The biodiversity present in the plant kingdom is often reflected in large qualitative and 443 
quantitative differences in metabolite composition in plant extracts. Indeed a plant population 444 
may display not only presence-absence polymorphism with regards to secondary metabolite 445 
composition but also quantitative differences between the concentrations of secondary 446 
metabolites [99]. There is indeed enormous qualitative diversity present in plant tissues and a 447 
large fraction is accounted from differential modification of common backbone structures 448 
which may have resulted from the evolution of enzymes with the same product specificity but 449 
catalysing different reactions [100]. A notable example of this includes flavonoids such as 450 
quercetin and their respective different glycoside derivatives which number over 130 [101]. 451 
Conversely, there are enzymes with poor substrate specificity that catalyse a similar reaction 452 
in more than a single extract, for example recombinant Vitis labrusca flavonoid 3-O-453 
glucosyltransferase was found to glycosylate both peonidin, malvidin and isorhamnetin [102]. 454 
Plant secondary metabolites are often involved in response to (a)biotic stresses and it has 455 
been recently demonstrated that plants can undergo rapid qualitative and quantitative 456 
evolution of secondary metabolites as a response to herbivore pressure [103, 104]. 457 
Interestingly, it can be observed that when plants are introduced into new habitats that it may 458 
favour the evolution of new secondary metabolite compositions compared with its native 459 
habitat [105, 106]. It has been suggested that synthesis of secondary plant metabolites are 460 
among the most evolvable traits as unlike primary metabolites their presence is not essential 461 
for plant survival under favourable ecological conditions [99]. The general lack of pleiotropic 462 
effects of mutations in the genes underlying the biosynthesis of secondary metabolites may 463 
allow these biochemical systems to be relatively free to evolve [107]. Under unfavourable 464 
ecological conditions on the other hand secondary metabolites may play important roles in 465 
chemical defense against natural plant enemies. According to the screening hypothesis, the 466 
high degree of diversity and evolvability present in some classes of compounds is explained 467 
by the increased chance to evolve the production of novel active compounds if they maintain 468 
a diverse and rapidly mutating complex of compounds [108], thus explaining the presence of 469 
a large complex of compounds with no known activity which could act as precursors for 470 
novel metabolites [99]. The variation present in the metabolite complement of plant tissues is 471 
ideally suited for analysis using metabolomics approaches which facilitates the development 472 
of chemotaxonomic studies with potential applications in drug discovery processes. 473 
The potential to categorise different accession/species according to chemical composition 474 
provides tools enabling the selection of plant raw materials, which display the broadest 475 
chemical diversity for bioprospection [109]. Additionally, the combination of 476 
chemotaxonomic studies with bioactivity data might aid the identification of chemical classes 477 
qualitatively and quantitatively overrepresented in plant species with medicinal properties 478 
[110]. A chemotaxonomic approach based on metabolite profiling of a collection of diverse 479 
indigenous Korean plant species showed clear separation according to family [111]. The 480 
authors subsequently combined the metabolite dataset with a bioactivity dataset to mine for 481 
correlations between individual metabolite levels and bioactivity which resulted in the 482 
identification of 5 metabolites with statistically significant correlations with bioactivity [111]. 483 
A similar strategy was employed to analyse nearly 90 species from the genus Rhododendron 484 
and correlate the metabolite profiles with plants extracts with antimicrobial and cytotoxity 485 
datasets resulting in the identification of seven metabolites with potential antimicrobial 486 
properties [112]. 487 
8. METABOLOMICS TOOLS FOR BIOPROSPECTING AND DEREPLICATION 488 
The analytical chemistry toolbox available for metabolomics approaches have historically 489 
been used in traditional NP discovery approaches particularly with respect to targeted 490 
metabolite profiling, structural elucidation, qualitative and quantitative assessment of purified 491 
NPs. Indeed there are numerous examples of bioprospection studies of plant extracts using 492 
MS and/or NMR tools [113-117]. However, the discovery of novel bioactive NPs faces 493 
challenges with respect to increasing rates of rediscovery of known compounds as active 494 
ingredients (replication) [118-120], high rates of attrition (lost to follow-up) in the translation 495 
of bioactivity due to unknown modes of action [121, 122] and difficulties in screening 496 
synergistic/antagonistic effects between multiple active compounds. As result “business as 497 
usual” in the field in bioprospecting is no longer an option if one is to address these 498 
challenges efficiently. Many are now turning to system-level approaches where the high-499 
throughput chemical characterization of complex compounds plays a central role and as result 500 
metabolomics-approaches are increasingly being used in multidisciplinary approaches to 501 
address these challenges. Metabolomics approaches are particularly suited for addressing the 502 
challenge of increasing rates of rediscovery of known compounds in the process of 503 
dereplication, which is the process of identifying already known bioactive molecules in 504 
extracts allowing researchers to focus their purification efforts on novel lead molecules and 505 
avoid redundant work [24]. As untargeted metabolomics approaches have gained attention 506 
due to high-throughput methods for the chemical characterisation of bioactive extracts, there 507 
has been increased development of workflows that take advantage of MS2 spectral 508 
information and high mass accuracy for rapid annotation of metabolites aligned with 509 
multivariate statistical analysis allowing for quick dereplication of complex extracts [24, 118, 510 
119, 123].  511 
When applied to the analysis of extracts from plants [124] or other organisms [120] these 512 
strategies can be successful and result in the identification of novel structures of the lead 513 
compounds thereby facilitating the pure compound screening approach (Figure 1) and avoid 514 
redundant work. The automated annotation of metabolomics datasets has been a central 515 
challenge in the field of metabolomics and has seen extensive development in the past 516 
decade. Therefore, continuing developments in this field and integration with known active 517 
ingredient libraries will ensure more efficient dereplication processes that can accelerate the 518 
process of bioprospection. 519 
9. METABOLOMICS FOR MODE OF ACTION AND DRUG METABOLISM 520 
The use of metabolomics tools has also seen application in the field of drug metabolism and 521 
toxicology and the elucidation the mode-of-action of lead compounds. The innovations 522 
observed in HTS have allowed a significant improvement in the level of automation of in 523 
vitro biochemical or cellular assays resulting in the systematic use in the early stages of drug 524 
discovery [96]. Isolated molecular target assays have been extensively employed in HTS 525 
approaches and often rely on the interaction between small molecules and protein targets. 526 
NMR methods in particular have seen extensive application not only for small molecule 527 
structure determination but also analysis of target-ligand complexes [125, 126]. Indeed, the 528 
analysis of protein ligand-interactions is of central importance for understanding the 529 
regulation of biological functions of target proteins, cooperativity of ligand mechanisms and 530 
the development of novel drugs that modulate protein functions or inhibit protein interactions 531 
[126].  532 
Alternatively, bioassays based on the use of microbial, animal and human cell culture 533 
metabolic models of human metabolism can provide an alternative source to animal 534 
experimentation in order to assess the effect drugs in putative human metabolism. In these 535 
instances metabolomics can be utilised as a tool to monitor cellular drug metabolism and 536 
assess the putative risks (or benefits) of drug metabolites in model organisms [96]. The use of 537 
metabolomics may be applied to rapidly evaluate the intracellular and extracellular 538 
metabolites and consequently evaluate cellular uptake, accumulation and metabolism of the 539 
tested drug/bioactive. The metabolomics approach when complemented with transcriptomic 540 
and proteomic data, can provide detailed mechanistic information of altered cellular 541 
processes [127, 128]. 542 
It was highlighted that the aforementioned reductionist approaches should be avoided when 543 
attempting to obtain evidence for the bioactivity of traditional medicines and that holistic 544 
approaches are advocated [41] which include in vivo approaches. Indeed, understanding the 545 
in vivo metabolic fate and mode of action of any potential drug candidate is of paramount 546 
importance for drug discovery and design [96]. The use of metabolomic-based approaches in 547 
the analysis of biofluids such as plasma or urine, has been explored widely within the context 548 
of the metabolic fate of potential drugs/bioactives [129, 130]. For example Sun et al (2009) 549 
investigated the excretion kinetic profile of acetaminophen in rats by profiling major drug 550 
metabolites (acetyl-L-cysteine acetaminophen) in urine utilising LC-MS and NMR 551 
metabolomics approaches. These results were correlated with endogenous oxidative stress-552 
related metabolites leading the authors to postulate that the toxicity of the drug can be 553 
monitored by utilising metabolomics tools [131]. A combined LC-MS and NMR 554 
metabolomics approach has also been applied for profiling urine, plasma and tissue samples 555 
from penicillin-treated rats revealing a decrease in many host-gut microbiota metabolites and 556 
urinary conjugated metabolites (sulphate, glucuronide and glycine conjugates) suggesting a 557 
strong interaction between gut-microbiota and drug metabolism [132]. These approaches 558 
have strong potential for application in screening drug metabolism, toxicity and compliance 559 
in the pre-clinical phases of the drug discovery process that are often associated with high 560 
levels of attrition.  561 
Metabolomics approaches have been routinely applied in the field of biomarker discovery 562 
with particular application in the field of cancer research [133-135] with an extensive body of 563 
literature reporting the identification of candidate metabolic biomarkers [134,136,137]. 564 
Indeed during cancer initiation and progression the cellular metabolism is altered allowing 565 
cells to increase anabolic synthesis, avoid apoptosis and adapt to low nitrogen and oxygen 566 
availability [138]. These extensive metabolic changes allow the discovery of multiple cancer 567 
biomarkers which can be monitored utilising metabolomics-based approaches [137,138]. In 568 
contrast with preclinical cancer studies where tissue and tumour samples are routinely 569 
collected, the regular monitoring of biomarkers in clinical setting often requires the use of 570 
minimally invasive low-cost methods for sample collection and analysis as they provide 571 
minimal discomfort to the patient and can be collected from control individuals [138]. 572 
Metabolomics-based methodologies could therefore provide robust low-cost solutions for the 573 
monitoring of multiple biomarkers with in various tissues but also extracellular fluids leading 574 
to potential applications in the assessment of disease progression, prognosis, treatment 575 
efficacy and drug metabolic effects in clinical settings [134]. As result, there has been an 576 
increasing interest in the application of metabolomics in the realm of cancer research and 577 
treatment. For example, a global untargeted mass spectrometry-based metabolomics approach 578 
was used in a preoperative window clinical trial of metformin for the treatment of 579 
endometrial carcinoma with the goal of monitoring of the metabolic effects of the drug 580 
treatment in serum (pre- and post-treatment) and tumour tissue [139]. Samples were collected 581 
from twenty obese patients and 65% were found to respond to the treatment, reducing 582 
proliferation of tumours based on pre- and post-treatment evaluation. The application of 583 
metabolite profiling tools to the analysis of serum samples indicated that responders to 584 
metformin treatment experienced a greater induction of lipolysis compared to non-responders 585 
and this correlated with increased fatty acid oxidation and glycogen metabolism observed in 586 
the patient’s tumour tissue [139]. This led the authors to suggest the potential use of 587 
metformin in the treatment of endometrial cancer in obese individuals. Subsequent work has 588 
been carried out in order to understand the mechanism of action behind the effect of 589 
metformin on cancer proliferation by applying a combined metabolomics and transcriptomics 590 
approach to study its effect over time in human-derived colon cancer LoVo cells. A total of 591 
47, 45 and 66 metabolites, ranging from carbohydrates to amino acids and lipids, were found 592 
to be differentially expressed at three time points. The majority of the metabolites 593 
experienced an upregulation 8h following exposure and were subsequently downregulated 594 
after 24h of exposure [140]. In combination with the transcriptome analysis the authors 595 
concluded that metformin is likely to modulate the cell energy metabolism at both 596 
metabolomics and transcriptomics level leading to the suppression of LoVo cell proliferation 597 
[140]. This illustrates the potential of metabolomics tools not only for providing insight into 598 
the drug mechanisms of action in models during the pre-clinical stages of drug development, 599 
but also for the monitoring of metabolic responses to the lead compound in patients during 600 
the clinical stages of drug development. 601 
 602 
10. METABOLOMICS OF COMPLEX COMPOUND MIXTURES AND 603 
INTEGRATION OF BIOACTIVITY DATA 604 
The use of complex mixtures of compounds such as typically found in extract libraries has 605 
traditionally been a challenge in NP discovery due to the diversity of small molecule present 606 
in varying levels some of which may interact and interfere in bioassays. As this is 607 
problematic for the identification of bioactive components in a single extract, the standard 608 
(reductionist) approach has been to generate fractions of reduced chemical complexity or 609 
testing pure compounds. However, with high-throughput screening and high-throughput 610 
chemical characterisation it is possible to generate a wealth of information regarding 611 
qualitative and quantitative differences in compounds mixtures for all the complex mixtures 612 
tested bioactivity. These multidisciplinary resources could then be data-mined in order to find 613 
correlations between chemical composition and bioactivity phenotype [141,142]. Compound 614 
activity mapping was developed by integrating high-content biological screening and 615 
untargeted metabolomics using a correlation of individual mass signals with specific 616 
phenotypes from a cell-based assay [141]. The authors combined 10 977 mass spectral 617 
features and 58 032 biological measurements from a library of 234 NP extracts which 618 
resulted in the identification of 13 clusters of fractions containing 11 known compound 619 
families and four new compounds. The authors found this methodology suitable for finding 620 
clusters containing single bioactives indicating a single mode of action. Furthermore clusters 621 
containing multiple bioactives were also reported which highlighted potential different modes 622 
of action although false positive compounds were also reported. Ultimately, in order to 623 
prevent false positives it is necessary that the extract libraries provide wide quantitative and 624 
qualitative chemical differences and minimize the occurrence of compounds that consistently 625 
share quantitative trends. It is proposed that screening larger libraries of extracts of similar 626 
organisms could aid in solving this problem [141]. 627 
CONCLUSION 628 
Metabolomics provides a wealth of tools with huge potential for aiding the process of 629 
drug/bioactive discovery from plant tissues (Figure 3). This process starts with the selection of 630 
target raw plant material and is often guided by ethnopharmacological leads. In addition, 631 
metabolomics can be used in the context of chemotaxonomy in order to identify sources of novel 632 
chemical entities, classes of compounds overrepresented in medicinal plants and novel plant 633 
sources for bioactive components. Furthermore, traditional bioprospection approaches rely on 634 
analytical tools integral to metabolomics such as NMR- and MS-based technologies. However, 635 
metabolomics aims to provide high-throughput chemical screening tools and these can be used 636 
for dereplication and identification of novel chemical entities with promising medicinal properties 637 
from complex plant extracts. When utilised as part of multidisciplinary approaches it provides the 638 
opportunity for mining the datasets in order to identify chemical diversity and potential novel 639 
leads for drug development as well as identifying the relevant biosynthetic pathways underlying 640 
the accumulation of bioactive components. Furthermore, metabolomics approaches can be 641 
applied to cellular, animal and human models in order to assess drug metabolism and 642 
mechanisms of action. Metabolomics can also be applied throughout the development of 643 
biotechnology-based approaches in order to identify promising metabolic engineering strategies 644 
and monitor unintended metabolic effects. Finally, analysis of biofluids utilising metabolomics-645 
based tools has great application potential for monitoring the drug metabolism response in model 646 
species. In summary, the metabolomics toolbox holds great potential for application throughout 647 
the process of drug and bioactive discovery, ranging from the screening of promising plant raw 648 
material for NPs to the elucidation of drug metabolism through the analysis of biofluids. 649 
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Figure 1 – Diagram representing the two leading approaches utilised in bioprospection of 1002 
bioactive compound:  pure compound screening (left) and bioassay-guided fractionation 1003 
(right). 1004 
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Figure 2 – Comparison of relative analyte coverage with respect to molecular mass, polarity 1007 
and concentration ranges across different analytical platforms. 1008 
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Figure 3 – Potential applications of metabolomics tools in the drug discovery workflow 1011 
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